Ten-year expericence of percutaneous radiofrequency ablation for hepatocelluar carcinoma. Background: OSI-Tar 725 is a phase II study assessing the efficacy of erlotinib, dosed to achieve a rash, in ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results